Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway

Chronic myeloid leukemia (CML) is a myeloproliferative pathology, originating from the hematopoietic cancer stem cells (hCSCs) due to the Bcl-Abl Philadelphia chromosome transformation. However, targeting these hCSCs as an effective anti-CML strategy is relatively less explored. Ovatodiolide (Ova) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Yue-Xing, Wang, Shi-Bing, Fu, Luo-Qin, Li, Shuang-Shuang, Guo, Qian-Peng, Wu, Yi, Mou, Xiao-Zhou, Tong, Xiang-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790462/
https://www.ncbi.nlm.nih.gov/pubmed/29423045
http://dx.doi.org/10.18632/oncotarget.23231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790462/
https://www.ncbi.nlm.nih.gov/pubmed/29423045
http://dx.doi.org/10.18632/oncotarget.23231

Ejemplares similares